TY - JOUR
AB - BJD British Journal of Dermatology Editor’s Choice October 2015 Alex Anstey aim of this study was to develop and characterize, from the mor- Tofacitinib, an oral Janus kinase inhibitor, for the treat- phological to the molecular level, a compromised reconstructed epidermis mimicking AD-related infl ammation in vitro. Normal ment of chronic plaque psoriasis: results from two human keratinocytes were used to generate reconstructed epider- mis, treated or not with an infl ammatory cocktail (polyinosin- randomized, placebo-controlled, phase III trials ic–polycytidylic acid, tumour necrosis factor-α, interleukin-4 and interleukin-13). Th e infl ammatory cocktail was reported to Th e authors of this study remind us that tofacitinib all P < 0.001). Higher PASI 75 rates were observed induce the following modifi cations to the model as observed in is an oral Janus kinase inhibitor being investigated with tofacitinib vs. placebo (OPT Pivotal 1, 39.9%, patients with AD: (i) it leads to spongiosis, (ii) it alters early and for psoriasis. Th e stated purpose of this study was 59.2% and 6.2%, respectively, for tofacitinib 5 mg terminal diff erentiation proteins, (iii) it increases thymic stromal to determine the 16-week effi cacy and safety of and 10 mg twice daily and placebo; OPT 
TI - Editor's Choice
JF - British Journal of Dermatology
DO - 10.1111/bjd.14150
DA - 2015-10-01
UR - https://www.deepdyve.com/lp/oxford-university-press/editor-s-choice-89ikGDuNPe
SP - i
EP - i
VL - 173
IS - 4
DP - DeepDyve
ER -